Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript
Source: SeekingAlpha
2026-03-02 16:37:53 ET
Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD March 2, 2026 7:30 AM EST...
Read the full article on Seeking Alpha
For further details see:
Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript
Ocular Therapeutix Inc.
NASDAQ: OCUL
OCUL Trading
-2.31% G/L:
$9.925 Last:
2,245,083 Volume:
$10.18 Open:
OCUL Latest News
March 09, 2026 04:01:00 pm
Ocular Therapeutix(TM) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL Stock Data
$2,007,118,202
193,092,608
0.71%
76
N/A
Biotechnology & Life Sciences
Healthcare
US
Bedford
